Scientists from the UK Health Security Agency (UKHSA) have achieved a milestone in vaccine innovation by supporting the development of a fridge-free tetanus and diphtheria vaccine, SPVX02, designed to overcome global cold-chain challenges.

Developed in collaboration with Stablepharma, the thermostable vaccine has successfully completed Phase I clinical trials. Laboratory testing and trial evaluations conducted at the UKHSA’s Vaccine Development and Evaluation Centre indicate that SPVX02 remains effective even after being stored at 30°C for up to 24 months, eliminating the need for refrigeration.

This breakthrough could transform global immunisation programmes by addressing one of the biggest barriers in vaccine distribution—the cold chain. Traditional vaccines require continuous refrigeration from manufacturing to administration and any disruption can lead to reduced efficacy and wastage. According to the World Health Organisation, nearly half of all vaccines are wasted globally, often due to cold-chain failures.

The fridge-free formulation of SPVX02 could significantly reduce vaccine wastage, simplify logistics and improve accessibility, especially in remote areas, disaster zones and regions with limited electricity infrastructure. The innovation also has the potential to reduce carbon emissions associated with temperature-controlled storage and transportation.

Following the promising Phase I results, SPVX02 will advance to Phase II clinical trials involving a larger group of healthy participants. The upcoming study will compare the vaccine’s effectiveness with an already licensed alternative in Europe, with trials expected to take place across the UK in the coming months. UKHSA will continue to support the programme by analysing immune responses during the study.

The SPVX02 initiative is backed by Innovate UK and the National Institute for Health and Care Research (NIHR) Southampton Clinical Research Facility, highlighting strong collaboration between government, academia and the biotech industry.

Experts believe fridge-free vaccines could play a crucial role in improving global health resilience. According to Bassam Hallis, such innovations could significantly enhance vaccine delivery worldwide, particularly in regions where maintaining a cold chain is difficult.

Similarly, Karen O’Hanlon emphasised that eliminating refrigeration requirements could lead to more equitable and sustainable healthcare systems, while also supporting pandemic preparedness and universal vaccine coverage goals.

Saul Faust noted that the collaboration has accelerated the translation of laboratory research into real-world clinical applications, reinforcing the UK’s leadership in vaccine innovation and deployment.

With SPVX02 progressing to the next phase of development, the technology represents a major step toward improving vaccine accessibility, reducing environmental impact and strengthening global immunisation strategies.